|
"ahn m j"的相關文件
顯示項目 1-10 / 72 (共8頁)
1 2 3 4 5 6 7 8 > >>
每頁顯示[10|25|50]項目
| 國立成功大學 |
2023 |
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
|
Hartmaier, R.J.;Markovets, A.A.;Ahn, M.J.;Sequist, L.V.;Han, J.-Y.;Cho, B.C.;Yu, H.A.;Kim, S.-W.;Yang, J.C.-H.;Lee, J.-S.;Su, W.-C.;Kowalski, D.M.;Orlov, S.;Ren, S.;Frewer, P.;Ou, X.;Cross, D.A.E.;Kurian, N.;Cantarini, M.;J�nne, P.A. |
| 國立成功大學 |
2023 |
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-na�ve, cisplatin-ineligible urothelial cancer
|
Galffy, Galffy G.;Lugowska, I.;Poddubskaya, E.V.;Cho, B.C.;Ahn, M.-J.;Han, J.-Y.;Su, W.-C.;Hauke, R.J.;Dyar, S.H.;Lee, D.H.;Serwatowski, P.;Estelles, D.L.;Holden, V.R.;Kim, Y.J.;Vladimirov, Vladimirov V.;Horvath, Z.;Ghose, A.;Goldman, A.;di, Pietro A.;Wang, J.;Murphy, D.A.;Alhadab, Alhadab A.;Laskov, M. |
| 國立成功大學 |
2023 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
|
Chan, A.T.C.;Lee, V.H.F.;Hong, R.-L.;Ahn, M.-J.;Chong, W.Q.;Kim, S.-B.;Ho, G.F.;Caguioa, P.B.;Ngamphaiboon, Ngamphaiboon N.;Ho, C.;Aziz, M.A.S.A.;Ng, Q.S.;Yen, C.-J.;Soparattanapaisarn, N.;Ngan, R.K.-C.;Kho, S.K.;Tiambeng, M.L.A.;Yun, T.;Sriuranpong, V.;Algazi, Algazi A.P.;Cheng, A.;Massarelli, E.;Swaby, R.F.;Saraf, Saraf S.;Yuan, J.;Siu, L.L. |
| 國立成功大學 |
2023 |
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Razak, A.R.A.;Wang, H.-M.;Chang, J.-Y.;Ahn, M.-J.;Munster, P.;Blumenschein, G.;Jr;Solomon, B.;Lim, D.W.-T.;Hong, R.-L.;Pfister, D.;Saba, N.F.;Lee, S.-H.;van, Herpen C.;Quadt, C.;Bootle, D.;Blumenstein, L.;Demanse, Demanse D.;Delord, J.-P. |
| 臺大學術典藏 |
2022-09-15T01:09:00Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|
Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; Chia-Chi Lin; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. |
| 臺大學術典藏 |
2022-09-15T01:08:59Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.; Chua K.L.M.; Chia-Chi Lin; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; Yang J.C.; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2022-08-19T06:48:41Z |
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
|
Kitagawa Y.; Matsumura Y.; Takazawa A.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU; Holtved E.; Xynos I.; Ahn M.-J.; Kadowaki S.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Okada M.; Kato K. |
| 臺大學術典藏 |
2022-08-10T02:37:43Z |
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
|
Tan W.L.; Chua K.L.M.; Lin C.-C.; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; CHIH-HSIN YANG; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. |
| 臺大學術典藏 |
2022-08-10T02:37:38Z |
Brigatinib Versus Crizotinib in ALK Inhibitor�VNaive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
|
Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garcia Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.I.; Gettinger S.N.; Tiseo M.; Lin H.M.; Liu Y.; Vranceanu F.; Niu H.; Zhang P.; Popat S. |
| 臺大學術典藏 |
2022-06-27T07:00:23Z |
First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study
|
Park K.; CHONG-JEN YU; Kim S.-W.; Lin M.-C.; Sriuranpong V.; Tsai C.-M.; Lee J.-S.; Kang J.-H.; Chan K.C.A.; Perez-Moreno P.; Button P.; Ahn M.-J.; Mok T. |
顯示項目 1-10 / 72 (共8頁)
1 2 3 4 5 6 7 8 > >>
每頁顯示[10|25|50]項目
|
